>PROKKA_00001 hypothetical protein
MSHVQHLTVIVTGWNKKLLNQAKEKAIELFTENMVTNTAKSLINQYESFMVCSSGSKGGW
EEDTEHKQKIEKYVKYLDSKAFSEKKHDNSLQYVVLSYGDSGSKVEKTNQIKKFN*
>PROKKA_00002 hypothetical protein
MFDIRVTDPKNEFYGQILKGSCFYYDIRHTGDSDDLYVAEAKDGRKINLLSSQIDEKHYH
NQELEKVTKEMGADIGDKVIIVETGSGSYSRDWETKGVHTITKIDFTGHVTFDNGNATIF
RPKVKVVTT*
>PROKKA_00003 hypothetical protein
MHLKTMKVIEFPKNKMVKDKMKKYKLETAIMMLEVLVDYDFTIIVNPKAAENIFNLPKNK
LIENFIITTDINKAEKLEIKKPCYYQLTGNELT*
>PROKKA_00004 hypothetical protein
METKDYGEIPYTIEIDWINETVWLNNHVAKEKIVVTEKDSKSIENAFKLIKAKRNGLL*
>PROKKA_00005 hypothetical protein
MNEIIVKGMFRMNKTKIKSIIVSIVLVSSLFIVSGCNLLENEYKQLQEHFKGRNAIITTY
DKESKPLDRIEGKSISISLDDKFKEQDEKGETIKKSSVLNITVGNNQIIHVGSSLILQED
GLQDLMKDTLKTTEIINQDKSRPFLRNIVDSYKNITSGKKRVILIRSQDGKPLATFVGDN
VSYFATDIPKSTGILIDGKYLLIYRCDYTIYDMDLIR*
>PROKKA_00006 Modification methylase RsrI
LLEVNNIYLGNCLEIMKKIDDKSIDMVLSDLPFEMTNNEWDKAIPFEPMWQEINRIAKDN
AVIALMAAGVFTSELVVSNKKYYRYSWIWKPKEKSNFLNANRMPLRQHIDIPIFYKSLPV
YNPQKTYGHKPVKKYKQHTTAGANYGKTKIGMEGGGQTDRYPTTIIDIPYNTIKIKDRIH
PTQKPVELYEYLIKTYTNEESIALDFTAGSCVLAEACINTNRNYICIEKEKKYCNKAKER
IKLHLEKGKQLKII*
>PROKKA_00007 hypothetical protein
MFWFDKENKDVIFMDNRELEDTLCDGRKLIIEPDILGDFRNIPYKDNSFKLVVFDPPHLI
KAGENSWLAKKYGKLNSDWPIDIRQGFNECMRVLDKYGILIFKWNEEQIKIKDILKVIDY
KPLLGNKRAKTHWLVFMKK*
>PROKKA_00008 hypothetical protein
MKVKLIDENKTEVQSSNKKEGNLINQLKFFGAIPTKESSLYTYFQFNGDIKTTMDNLGFR
I*
>PROKKA_00009 hypothetical protein
MIKTKLFTGLTALEAVYDYQDFIKRNQNFEIISVNILKDNFVLLTYKKSKKDIKG*
>PROKKA_00010 hypothetical protein
MISIKRKDEIWNAIYAEPCLLDFNTLNTEELSFAIGIIISAGSRNSFKKKHFNKEQLKFL
QKVFKELLETMK*
>PROKKA_00011 hypothetical protein
MLEAKLDNHLGYSKYDYENKILQIVGAVVVLKSIIRFKGI*
>PROKKA_00012 Botulinum neurotoxin type B precursor
MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFN
KSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLG
DRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNH
FASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLY
GIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIV
DRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETN
IAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKNMEKEYRGQNKAINKQA
YEEISKEHLAVYKIQMCKSVRAPGICIDVDNEDLFFIADKNSFSDDLSKNERIEYDTQSN
YIENRSSIDELILDTNLISKIELPSENTESLTDFNVDVPVYEKQPAIKKFFTDENTIFQY
LYSQTFPLDIRDISLTSSFDDALLFSNKVYSFFSMDYIKTANKVVEAGLFAGWVKQIVDD
FVIEANKSNTMDKLADISLIVPYIGLALNVGNETAKGNFENAFEIAGASILLEFIPELLI
PVVGAFLLESYIDNKNKIIKTIDNALTKRDEKWRDMYGLIVAQWLSTVNTQFYTIKEGMY
KALNYQAQALEEIIKYKYNIYSEKEKSNINIDFNDINSKLNEGINQAIDNINNFINECSV
SYLMKKMIPLAVEKLLDFDNTLKKNLLNYIDENKLYLIGSAEYEKSKVDKHLKTIIPFDL
SMYTNNTILIEIFNKYNSEILNNIILNLRYRDNNLIDLSGYGANVEVYDGVELNDKNQFK
LTSSTNSEIRVTQNQNIIFNSMFLDFSVSFWIRIPKYKNDGIQNYIHNEYTIINCIKNNS
GWKISIRGNRIIWTLTDINGKTKSVFFEYSIREDISDYINRWFFVTITNNSDNAKIYING
KLESNIDIKDIGEVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIKEIYKIQSY
SEYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSNYINYRNLY
IGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYALKNFKKKEEKLFLAPISD
SDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFKDYKYYFCIS
KWYLKEVKRKPYNPNLGCNWQFIPKDEGWIE*
>PROKKA_00013 Botulinum neurotoxin type A precursor
MCVEINLGEWLDMNINDNLSINSPVDNKNVVVVRARKTDTFFKAFKVAPNIWVAPERYYG
ESLSIDEEYKVDGGIYDSNFLSQDSEKDKFLQAIITLLKRINSTNAGEKLLSLISTAIPF
PYGYIGGGYYAPNMITFGSAPKSNKKLNSLISSTIPFPYAGYRETNYLSSEDNKSFYASN
IVIFGPGANIVENNTVFYKKEDAENGMGTMTEIWFQPFLTYKYDQFYIDPAIELMKCLIK
SLYFLYGIKPSDDLVVPYRLRNELENIEYSQLDIVDLLVSGGIDPKFINTDPYWFIDNYF
SNAKKMFEDHRNIYETEIEGNNAIGNDIKLRLKQKFRININDIWELNLNYFSKEFNIMMP
DRFNNALKHFYRKQYYKIDYPENYSINGFVNGQINAQLSLSDRNQDIINKPEEIINLLNE
NNVLLMRSNIYGDGLKSTVDDFYSNYKIPYNRAYEYHFNNSNDSSLDNVNVGVIDNIPEI
IDVNPYRKNCDPFTPVYNITETKEINTTIPFSVNYLQAQNANNEKFSLSSDFVEVVSSKD
KSLAYSFLSNVMFYLDSIKDNSPIDTDKEYYLWLREIFRNYSFDITATQEINTNCGINKV
VTWFGKALNILNTSDSFVEEFQNLGPISLINKKENLSMPIIEIYEIPNDMLGLPLNDLNE
KLFNIYLKNILYFKKVYFNFLDQWWTEYYSQYFDLICMAKQSILAQEKLIKQIIQNKLQD
LSKADISMDKLNLMNLATEKTFIDLSNESQIAINNINDFLNKSAICVFDTNIYPKFISFM
EQCINSVNSNVTAFIQKCTNITEDEKLQLIKLNTFMNIDFEFFDIQSIKDLITSETDLIK
EEKESDYNLFLFTLQEDNNKVIEDISGKNTLVKYSDSISLVYGVNGDALYLKEPDESVSF
SNKAFENGLTNSFSICFWLRNLGEDIITSKLIENKADNCGWEIYFQNNGLVFSIVDCNGN
EENIYLSDVISKNWYYISISIDRLRNQLLIFINDKLIANQSIEQILNIYSSNTISLVNGN
NPIYVEGLSILNRSITSEEVVNNYFSYLNNSYIRDISGERLEYNKTYELYNYVFPENSLY
EVTENNNIYLSIKDTNNLNIQGAKFKLINIDTNKQYVQKWDEGVVCLLGDEEKYVDISSE
NNRIQLVSSKDTAKRIIFNNDIFRPNCLTFAYNNKYLSLSFRDRNYNWMICNNNDNIPKA
AHLWALKGI*
>PROKKA_00014 transcriptional regulator BotR, P-21
MNKLFLQIKMLKSDNGEFQEIFKHFEKTINIFTRKYNIYDNYNDILYHLWYTLKKVDLSN
FNTQNDLERYISRTLKRYCLDICNKRKIDKKIMYNSEIVDKKLSLIANSYSSYLEFEFND
LISILPDDQKKIIYMKFVEDIKEIDIAKKLNISRQSVYKNKILALERLEPILKKLINM*
>PROKKA_00015 hypothetical protein
MEHYSTIQNSLNDKIVTISCKANTDLFFYQVPGNGNVSLFQQTRNYLERWRIIYDSNKAA
YKIKSMNIYNTNLVLTWNAPTHNISAQQDSNADNQYWLLLKDIGNNSFIIASYKNPNLVL
YADTVAHNLKLSTLNNSSYIKFIIEDYIISDLNNFTCKISPILAGNKVVQQVSVTNLAVN
LYTWNNDRNQKWTIIYNEEKAAYQFFNKILSNGVLTWIFSEGNTVRVSSSAQNNDAQYWL
INPVSDNYDRYTITNLRDKTKALDLYGGQTADGTTIQVFNSNGGDNQIWTMRDL*
>PROKKA_00016 HA 17 kDa subunit
MSVERTFLPNGNYNIKSIFSDSLYLNPVSGSLTFSNESSANNQKWNVEYMAENRCFKISN
VAEPNKYLSYDNFGFISLDSLSNRCYWFPIKIAVNTYIMLSLNKVNELDYAWDIYDTNEN
ILSQPLLLLPNFDIYNSNQMFKLEKI*
>PROKKA_00017 Hemagglutinin components HA-22/23/53 precursor
MNSSIKKIYNDIQEKVINYSDTIDLADGNYVVSRGDGWILSRQNQILGGSVISNGSTGIV
GDLRVNDNAIPYYYPTPSFNEEYIKNNIQTVFANFTEANQIPIGFEFSKTAPSNKNLYMY
LQYTYIRYEIIKVLQHEIIERAVLYVPSLGYVKSIEFNPGEKINKDFYFLTNDKCILNEQ
FLYKKILETTKNIPTNNIFNSKVSSTQRVLPYSNGLYVINKGDGYIRTNDKDLIGTLLIE
AGSSGSIIQPRLRNTTRPLFTTSNDAKFSQQYTEERLKDAFNVQLFNTSTSLFKFVEEAP
SNKNICIKAYNTYEKYELIDYQNGSIVNKAEYYLPSLGYCEVTNAPSPESEVVKTQVAED
GFIQNGPEEEIVVGVIDPSENIQEINTAISDNYTYNIPGIVNNNPFYILFTVNTTGIYKI
NAQNNLPPLKIYEAIGSGNRNFQSGNLCDDDIKAINYITGFDSPNAKSYLVVLLNKDKNY
YIRVPQTSSNIENQIKFKREEGDLRNLMNSSVNIIDDLNSTGAHYYTRQSPDVHDYISYE
FTVPGNFNNKDTSNIRLYTSYNQGIGTLFRVTETIDGYNLINIQQNLNLLNSTKSIRLLN
GAIYILKVEVTELNNYNIRLHIDITN*
>PROKKA_00018 hypothetical protein
MLIYISDEEYNSFDISDILNSPNIIEEKVLSELNNYQNYIDIKTNELEYKLNFEQNNQIL
EGTTLDKIQSIDIAKELVEKSKNEILVNTNVILLQSSLENDKNYILTLLR*
>PROKKA_00019 hypothetical protein
MVDKHNIKTVFTSKYGYKNNDDIDIANVSNNINKMFSINGTINDNLKVKGYLQEEDNKLI
GNINDKEYNIQLEITMEDALKTTIINKNDHTFRGDTSIVDIRDNLGMTYTSKEIRVYEFK
EIIANDKSNNKNKQIVFELPNNKKLTFDINNKNVNLYI*
>PROKKA_00020 transposase, IS605 OrfB family
LKLAFKFNPKLNSLQSSIIEELSYHTTNLYNIANYDNLQKGVKSYLQMNTMYNINWHKDF
LHSHNYQHCLRVLEKNWKSYFKAIIDYKKNPSKYLGNPRPPKYKNHNDRKNEVIFTKAGI
RFKNNTLMLSLSKAMKVEYGVKSLNFEVSDKLQGLLNWNGLNQVKIKWDNSIKRWYLIII
YEKEENLIPEDFSNIMSIDLGLNNLATITFLKNEDSHIINGKPLKSVNSFVNKKIACLQS
IAMSMTGSAKHKDTKAITKLRRYRENYINNYLHKASRQVIELALNYKVKTIVIGDIKGIK
QNMNYAKTFVQIPIQRFRELIEYKARLLGIEVQYQKKAYSSGCSALDLESINKVSYNKNR
RIYRGLFKSNTDIKINADVNGSLNILRLYVN*
>PROKKA_00021 hypothetical protein
MCDKKYIIEFLIYLSIVILVIIISGGVCMYTFNFKQIIIRLI*
>PROKKA_00022 hypothetical protein
MKIKHPKVNEYYNYLKKSFANVNLSEEHRMDIYKRIEIIEALVSLYEQKYEFDDEIIEDL
KLKYRPVFPEELKNIQKNLEKAIIK*
>PROKKA_00023 Transposase
MDLDTNNHSVFLLHYHLVLVIKYRREVINADISNRLKEIFEKISPKYNISIEEWEHDNNH
VHVLFKAQPNSELSKFINAYKSASSRLIKKEFPEIKKKLWKEYFWSRSYCLLTTGGSPIE
VIKKYIQNQGKK*
>PROKKA_00024 transposase, IS605 OrfB family
LLKAYEYRIYPNSEQRLYLAKTFGCTRFIYNKMLADRIRLYEENKDLGIKKVKYPTPAQY
KKEFPWLKEVDSLALANAQLNLHKAYKNFFRDKSIGFPKFKSKKSNYHSYTTNNQKGTVC
IENGYIKIPKLKSMIKIKLHRQFNGLIKSCTVSKTPSNKYYVSILADTENIKLPKVENKI
GVDVGLKEFAICSNGDRYDNPKWLRKSEKRLKKLQKDLSRKKKGSNNLYKARLKVARLHE
RITNQRKDFLHKLSTKLIRENQTIVIEDLKVKNMMKNDKLSKAIGEVSWFEFRRMLEYKA
EWNDKKIVIAPSNYASSQLCSDCGYKNKEVKNLGLREWTCPKCNTKHDRDINASKNLLKL
AI*
